文献速递艾滋病与性传播感染病毒性肝炎

真实世界中HIV/HCV合并感染者接受DAA治疗期间抗逆转录病毒药物血浆谷浓度研究

Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

总体上DAA治疗前后抗逆转录病毒药物谷浓度无显著差异,但接受2D/3D方案者达芦那韦谷浓度显著下降40.9%。

要点

  • DAA治疗期间多数抗逆转录病毒药物谷浓度与治疗前无显著差异
  • 2D/3D方案者达芦那韦谷浓度显著下降,需关注DDI
  • 接受抗HCV治疗时可考虑监测抗逆转录病毒药物血浆浓度

核心结论

  • 真实世界中HIV/HCV合并感染者DAA治疗期间抗逆转录病毒药物血浆浓度总体与抗HCV治疗前无差异。
  • 2D/3D方案者达芦那韦浓度显著降低,虽样本量小。

研究设计与样本

  • DAA治疗前及治疗2个月后采血,用HPLC-UV测定抗逆转录病毒药物谷浓度,并评估自我报告依从性。

主要发现

  • 2D/3D组治疗前和治疗中谷浓度不达标分别为3例(10.3%)和3例(10.3%),索磷布韦为基础方案组分别为16例(14.8%)和11例(10.2%)。
  • 2D/3D组达芦那韦谷浓度中位数治疗中为1125 ng/mL(IQR 810-1616),治疗前为1903 ng/mL(IQR 1387-3983),下降40.9%(n=5;P=0.009)。
  • 2D/3D组阿扎那韦或雷特格韦浓度无差异;索磷布韦为基础方案组所有抗逆转录病毒药物谷浓度治疗前后相似。
  • 自我报告抗逆转录病毒药物依从性始终≥93%。

关键数值与推荐

  • 达芦那韦谷浓度中位数:治疗中1125 ng/mL(IQR 810-1616)对比治疗前1903 ng/mL(IQR 1387-3983),n=5,P=0.009。
  • 2D/3D方案占21.2%,索磷布韦为基础方案占78.8%。

临床怎么用

  • 对接受2D/3D方案的HIV/HCV合并感染者应关注达芦那韦浓度下降及药物相互作用。
  • 抗HCV治疗期间监测抗逆转录病毒药物血浆浓度可为管理合并感染者提供有用信息。

局限性

  • 达芦那韦浓度分析仅5例,样本量小。
  • 为单中心观察性研究,依从性为自我报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Possible drug-drug interactions (DDIs) between antiretrovirals (ARVs) and direct-acting antiviral agents (DAAs) are of some concern. OBJECTIVES: To investigate ARV plasma trough concentrations (Ctrough) before and during DAAs in patients treated in the real world. METHODS: Single-centre, prospective, observational study including HIV/HCV coinfected persons undergoing DAA treatment. Self-reported adherence was assessed and ARVs Ctrough measured by HPLC-UV. Blood samples were collected before and after 2 months of DAA treatment. RESULTS: One-hundred and thirty-seven patients were included: 21.2% treated with ombitasvir/paritaprevir/ritonavir ± dasabuvir (2D/3D) and 78.8% with sofosbuvir-based regimens. Suboptimal Ctrough before and during DAA was found, respectively, in 3 (10.3%) and 3 (10.3%) cases treated with 2D/3D, and 16 (14.8%) and 11 (10.2%) with sofosbuvir-based regimens, even if self-reported ARV adherence was always ≥93%. In 2D/3D-treated patients, median darunavir Ctrough during DAAs was significantly lower than observed before DAAs [1125 ng/mL (IQR, 810-1616) versus 1903 ng/mL (IQR 1387-3983), respectively] (n = 5; P = 0.009), with a 40.9% decrease. In the same group, no differences in atazanavir or raltegravir concentrations were found. In patients treated with sofosbuvir-based regimens, Ctrough of all ARVs were similar before and during DAAs. CONCLUSIONS: In the real world of HIV/HCV coinfected patients, ARV plasma concentrations during DAAs were generally not different from those found before anti-HCV treatment. Although assessed in a small number of patients, darunavir concentrations during 2D/3D showed a significant reduction when compared with those found before DAAs. ARV plasma concentrations measurement during anti-HCV treatment may give useful information for managing HIV/HCV coinfected persons receiving treatment for both infections.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Tempestilli M, Fabbri G, Mastrorosa I, et al. Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world. J Antimicrob Chemother. 2018. PMID: 29106584. doi:10.1093/jac/dkx348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。